Neil Iyengar, MD

In the program's closing segment, the panel shares practical pearls and reflections for clinicians.

The panel explores the rationale and emerging data for combining ADCs with immunotherapy and other targeted agents.

The panel discusses the notably low treatment discontinuation rates seen with ADCs in both pivotal trials compared with chemotherapy, and whether these reassuring numbers translate to real-world practice.

The panel reviews the distinct adverse event profile associated with datopotamab deruxtecan, moving from least to most common.

The panel takes a deeper look at neutropenia, one of the adverse events of special interest with sacituzumab govitecan.

The panel addresses one of the field's most pressing practical questions: what to offer after a first-line ADC, acknowledging that no prospective data yet exist to guide the decision.

The panel explores how to assign value to different trial endpoints in an aggressive disease, discussing overall survival as the gold standard while considering how crossover and confounding factors complicate its interpretation, and where PFS2 fits as a measure that reflects benefit across lines of therapy.

With both pivotal trials reviewed, the panel discusses how to reconcile the data when counseling an individual patient.

The panel reviews the TROPION-Breast02 findings, offering equipoise alongside the prior discussion of ASCENT-03.

In the closing segment, Dr. Neil Iyengar invites Dr. Kelly McCann and Dr. Alison Conlin to reflect on how emerging evidence is shaping the future management of HER2-positive early breast cancer.

Dr. Neil Iyengar concludes the case-based discussion by exploring the role of multidisciplinary care in the management of HER2-positive early breast cancer following neoadjuvant therapy.

Dr. Neil Iyengar presents a second clinical scenario focused on a patient with residual invasive disease following neoadjuvant therapy for HER2-positive early breast cancer, prompting Dr. Alison Conlin and Dr. Kelly McCann to discuss adjuvant treatment decision-making.

The panel takes a closer look at ASCENT-03, framing it as a study designed to test whether a TROP2-directed ADC could serve as a first-line alternative to chemotherapy.

The panel turns to the design of two pivotal first-line trials, framing the discussion not as a head-to-head comparison but as a way to inform patient selection in clinic.

Dr. Neil Iyengar presents a clinical scenario involving a patient with high-risk HER2-positive early breast cancer, prompting Dr. Kelly McCann and Dr. Alison Conlin to discuss practical treatment selection in the neoadjuvant setting.

Dr. Neil Iyengar leads a discussion with Dr. Kelly McCann and Dr. Alison Conlin on balancing efficacy with safety when incorporating newer therapies into the management of HER2-positive early breast cancer.

The panel addresses one of the more difficult challenges in metastatic TNBC: central nervous system involvement.

The panel discusses the rationale for using effective agents in the first-line metastatic setting rather than reserving them for later lines, considering the disease's aggressive course and limited expected survival alongside the trajectories seen in other breast cancer subtypes.

The panel reviews how the metastatic TNBC treatment paradigm has evolved, tracing TROP2-directed ADCs from later-line use into the first-line setting.

Dr. Neil Iyengar shifts the discussion to the management of residual disease in HER2-positive early breast cancer, inviting Dr. Alison Conlin to review the phase III DESTINY-Breast05 trial.

Dr. Neil Iyengar shifts the discussion to the management of residual disease in HER2-positive early breast cancer, inviting Dr. Alison Conlin to review the phase III DESTINY-Breast05 trial.

The panel grounds the discussion in the biology and natural history of metastatic triple-negative breast cancer, framing it as a high-proliferation subtype prone to rapid resistance, in which the first-line setting offers an important opportunity to influence outcomes. Panelists outline a biomarker-driven treatment algorithm stratified by PD-L1 status, germline BRCA status, and prior early-stage therapy, touching on immune checkpoint inhibition, PARP inhibitors, platinum-based chemotherapy, and the role of antibody-drug conjugates across lines of therapy.

Dr. Neil Iyengar continues the discussion on HER2-positive early breast cancer by exploring how the DESTINY-Breast11 findings may translate into routine clinical practice.

Dr. Neil Iyengar moderates a discussion with Dr. Alison Conlin and Dr. Kelly McCann on the design of the DESTINY-Breast11 trial and its implications for the management of HER2-positive early breast cancer.

Drs. Neil Iyengar and Kelly McCann review the phase III DESTINY-Breast11 trial, highlighting its design, patient population, and key findings demonstrating improved pathologic complete response rates with a trastuzumab deruxtecan–based neoadjuvant regimen in high-risk HER2-positive early breast cancer.

Drs Park and Iyengar discuss the evolving treatment paradigm for TNBC, the integration of metabolic health strategies, and the clinical emergence of ADCs.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, outline key future directions for antibody-drug conjugate (ADC) development in breast cancer.

Drs Nunnery and Iyengar highlight the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates have altered the HER2-positive breast cancer treatment paradigm.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss the role of antibody-drug conjugates in the management of hormone receptor–positive breast cancer.